Predictive Factors Associated with Liver Fibrosis and Steatosis by Transient Elastography in Patients with HIV Mono-infection Under Long-term Combined Antiretroviral Therapy
Overview
Authors
Affiliations
Introduction: Non-alcoholic fatty liver disease is characterized by the presence of hepatic steatosis and can be associated with fibrosis progression, development of cirrhosis and liver-related complications. Data on the prevalence of liver fibrosis and steatosis in HIV patients remain contradictory in resource-limited settings. We aimed to describe the prevalence and factors associated with liver fibrosis and steatosis in patients with HIV mono-infection under long-term antiretroviral therapy (ART) in Rio de Janeiro, Brazil.
Methods: Clinical assessment, fasting blood collection and liver stiffness measurement (LSM)/controlled attenuation parameter (CAP) by transient elastography were performed on the same day for this cross-sectional study (PROSPEC-HIV study; NCT02542020). Patients with viral hepatitis co-infection, ART-naïve or missing data were excluded. Liver fibrosis and steatosis were defined by LSM ≥ 8.0 kPa and CAP ≥ 248 dB/m respectively. HIV history, cumulative and current ART regimens were evaluated. Multivariate logistic regression models adjusted for age and gender were performed.
Results: In total, 395 patients (60% female; median age of 45 (IQR, 35 to 52) years, body mass index = 25.7 (23.2 to 29.4) kg/m , alanine aminotransferase = 30 (23 to 42) IU/L, duration of ART for 7 (4 to 14) years) were included. LSM and CAP were reliable in 93% (n = 367) and 87% (n = 344) respectively. The prevalence of fibrosis and steatosis were 9% (95% confidence interval (CI), 7 to 13) and 35% (95% CI, 30 to 40) respectively. The following factors were associated with fibrosis (odds ratio (OR) (95% CI)): older age (per 10 years; 1.80 (1.27 to 2.55); p = 0.001) and CD4+ count <200 cells/mm (7.80 (2.09 to 29.09), p = 0.002). Type 2 diabetes had a trend towards the presence of liver fibrosis (2.67 (0.96 to 7.46), p = 0.061). Central obesity (10.74 (4.40 to 26.20), p < 0.001), type 2 diabetes (9.74 (3.15 to 30.10), p < 0.001), dyslipidaemia (2.61 (1.35 to 5.05), p = 0.003) and metabolic syndrome (4.28 (2.45 to 7.46), p < 0.001) were associated with steatosis. A dominant backbone ART regimen of zidovudine (AZT), d4T, ddI or ddC was associated with steatosis (1.90 (1.07 to 3.38), p = 0.028) independently of metabolic features.
Conclusion: Integrated strategies for preventing non-communicable diseases in people with HIV mono-infection are necessary to decrease the burden of liver diseases. Clinical Trial Number: NCT02542020.
Almeida C, Arantes Ferreira Peres W, Silva P, Santos de Aguiar Cardoso C, de Andrade M, Castro-Alves J Metabol Open. 2024; 24:100334.
PMID: 39717737 PMC: 11664064. DOI: 10.1016/j.metop.2024.100334.
Odeghe E, Oyeleke G, Odofin M, Duguru M, Davwar P, Nyam D J Int Assoc Provid AIDS Care. 2024; 23:23259582241292511.
PMID: 39469965 PMC: 11528674. DOI: 10.1177/23259582241292511.
Rose P, Davies C, Cotton M, Otwombe K, Browne S, Vaida F AIDS. 2024; 38(11):1638-1647.
PMID: 38905492 PMC: 11317452. DOI: 10.1097/QAD.0000000000003964.
van Eekeren L, Vadaq N, Vos W, Blaauw M, Groenendijk A, van Lunzen J Open Forum Infect Dis. 2024; 11(6):ofae266.
PMID: 38868310 PMC: 11167668. DOI: 10.1093/ofid/ofae266.
Cardiometabolic health in people with HIV: expert consensus review.
Batterham R, Bedimo R, Diaz R, Guaraldi G, Lo J, Martinez E J Antimicrob Chemother. 2024; 79(6):1218-1233.
PMID: 38656584 PMC: 11144490. DOI: 10.1093/jac/dkae116.